Valuation: Morepen Laboratories Limited

Market Cap 5.04TCr 54Cr 48Cr 44Cr 40Cr 76Cr 78Cr 529.85Cr 211.28Cr 2.69TCr 201.29Cr 196.98Cr 8.49TCr P/E 2025
21.8x
P/E 2026 19.5x
Enterprise Value 5.19TCr 55Cr 50Cr 45Cr 41Cr 78Cr 80Cr 546.02Cr 217.72Cr 2.77TCr 207.43Cr 202.99Cr 8.75TCr EV / Sales 2025
1.45x
EV / Sales 2026 1.11x
Free-Float
57.95%
Yield 2025
0.42%
Yield 2026 0.59%
1 day-4.96%
1 week-19.09%
Current month-19.09%
1 month-36.00%
3 months+15.75%
6 months+111.20%
Current year+124.01%
1 week 92
Extreme 92
108.05
1 month 92
Extreme 92
148.25
Current year 33.44
Extreme 33.44
150.8
1 year 33.44
Extreme 33.44
150.8
3 years 33.44
Extreme 33.44
150.8
5 years 23.65
Extreme 23.65
150.8
10 years 7.21
Extreme 7.21
150.8
Manager TitleAgeSince
Chief Executive Officer 58 01/07/2026
Chief Executive Officer 62 01/02/1992
Director of Finance/CFO 59 03/04/2002
Director TitleAgeSince
Chairman 62 01/02/1992
Director/Board Member 58 13/08/2019
Director/Board Member 58 13/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
-4.96%-19.09%+93.93%+157.20% 54Cr
-0.79%-4.48%+44.44%+127.49% 1,20600Cr
+1.43%+1.11%+47.73%+82.08% 66TCr
+1.07%-1.21%+32.99%+106.31% 51TCr
-0.36%-3.25%+47.17%+64.58% 38TCr
-0.14%-1.87%+71.05%+40.63% 36TCr
-0.78%-0.52%+30.57%+57.98% 31TCr
-0.80%-0.21%+8.54%+35.56% 29TCr
+0.03%-1.20%+45.89%+68.76% 25TCr
-0.41%-2.22%+35.24%+105.68% 21TCr
Average -0.57%-3.29%+45.76%+84.63% 41.8TCr
Weighted average by Cap. -0.05%-1.96%+42.25%+88.39%

Financials

2025 2026
Net sales 1.81TCr 19Cr 17Cr 16Cr 14Cr 27Cr 28Cr 190.41Cr 76Cr 966.62Cr 72Cr 71Cr 3.05TCr 1.81TCr 19Cr 17Cr 16Cr 14Cr 27Cr 28Cr 189.79Cr 76Cr 963.48Cr 72Cr 71Cr 3.04TCr
Net income 118.02Cr 1.26Cr 1.13Cr 1.03Cr 93.94L 1.77Cr 1.83Cr 12Cr 4.95Cr 63Cr 4.71Cr 4.61Cr 198.8Cr 95Cr 1.01Cr 90.52L 82.73L 75.52L 1.42Cr 1.47Cr 9.97Cr 3.98Cr 51Cr 3.79Cr 3.71Cr 159.82Cr
Net Debt -9L -9.87T -8.85T -8.09T -7.39T -13.92T -14.36T -97.54T -38.89T -5L -37.05T -36.26T -15.63L 153.79Cr 1.64Cr 1.47Cr 1.34Cr 1.22Cr 2.31Cr 2.38Cr 16Cr 6.45Cr 82Cr 6.14Cr 6.01Cr 259.06Cr
Projected Income Statement - Annual - Morepen Laboratories Limited
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,919
Date Price Change Volume
06/26/06 ₹92.00 -4.96% 10,53,445
05/26/05 ₹96.80 -3.44% 9,02,007
04/26/04 ₹100.25 -2.34% 7,57,588
03/26/03 ₹102.65 -5.00% 40,442
02/26/02 ₹108.05 -4.97% 54,119
  1. Stock Market
  2. Stocks
  3. MOREPENLAB Stock